For example, BEZ-235, in combination with EGFR inhibitors, is more effective for less mTOR inhibitor-sensitive and EGFR inhibitor-resistant CRC cell lines, especially HCT116 (which harbors KRAS and PIK3CA mutations), as shown in a recent study [39]. The gene discussed is KRAS; the disease is colorectal carcinoma.